Literature DB >> 2447480

Effect of avermectin B1a on chick neuronal gamma-aminobutyrate receptor channels expressed in Xenopus oocytes.

E Sigel1, R Baur.   

Abstract

Chick brain mRNA was isolated and injected into Xenopus oocytes. This led to the expression of gamma-aminobutyrate (GABA) channels easily accessible for current measurements using the voltage clamp technique. The effect of the anthelmintic natural product avermectin B1a on the GABA current was studied quantitatively. In the presence of the drug, GABA-induced chloride currents were strongly enhanced in a dose-dependent manner. Half-maximal stimulation of the current evoked by 5 microM GABA was found with about 0.1 microM avermectin B1a. Avermectin B1a did not affect the reversal potential of the current or the maximal response elicited by GABA, and did not alter the membrane permeability in the absence of GABA. The major effects of avermectin B1a were a shift of the Ka for GABA from 21 microM to 2 microM, and a decrease of the apparent Hill coefficient for GABA from 1.7 to 1.1. Furthermore, in the presence of avermectin B1a, desensitization of the GABA current was strongly inhibited. The benzodiazepine-binding site ligand Ro 15-1788 did not affect the action of avermectin B1a if present at concentrations up to 1 microM. The stimulatory effects of the drug were additive to the ones by the barbiturate pentobarbital, if both agents were added at low concentrations. At higher concentrations each of these agents inhibited the stimulatory effects of the other.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447480

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

Review 1.  Allosteric modulation of ATP-gated P2X receptor channels.

Authors:  Claudio Coddou; Stanko S Stojilkovic; J Pablo Huidobro-Toro
Journal:  Rev Neurosci       Date:  2011-03-16       Impact factor: 4.353

Review 2.  Use of Xenopus oocytes for the functional expression of plasma membrane proteins.

Authors:  E Sigel
Journal:  J Membr Biol       Date:  1990-09       Impact factor: 1.843

3.  Nicotinic acetylcholine receptor transmembrane mutations convert ivermectin from a positive to a negative allosteric modulator.

Authors:  Toby Collins; Neil S Millar
Journal:  Mol Pharmacol       Date:  2010-05-12       Impact factor: 4.436

Review 4.  Inhibitory glutamate receptor channels.

Authors:  T A Cleland
Journal:  Mol Neurobiol       Date:  1996-10       Impact factor: 5.590

Review 5.  Ion channels: molecular targets of neuroactive insecticides.

Authors:  Valérie Raymond-Delpech; Kazuhiko Matsuda; Benedict M Sattelle; James J Rauh; David B Sattelle
Journal:  Invert Neurosci       Date:  2005-10-24

6.  avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans.

Authors:  J A Dent; M W Davis; L Avery
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

7.  Ivermectin activates GIRK channels in a PIP2 -dependent, Gβγ -independent manner and an amino acid residue at the slide helix governs the activation.

Authors:  I-Shan Chen; Michihiro Tateyama; Yuko Fukata; Motonari Uesugi; Yoshihiro Kubo
Journal:  J Physiol       Date:  2017-07-30       Impact factor: 5.182

Review 8.  Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.

Authors:  Jingyi Wang; Jon Lindstrom
Journal:  Br J Pharmacol       Date:  2017-03-20       Impact factor: 8.739

Review 9.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 10.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.